EIKN — Eikon Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1861123 ·
Last close
$5.15
Market Cap
$279.06M
52W High
$17.40
52W Low
$4.95
ADV30
541,008
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -90,552,000 | -86,112,000 | 706,201,000 | 98,482,000 | 321,908,000 |
| Jun 2026 | 0 | — | -93,394,000 | -88,409,000 | 779,570,000 | 142,613,000 | 313,070,000 |
| Mar 2026 | 0 | — | -87,337,000 | -82,958,000 | 850,826,000 | 161,154,000 | 300,155,000 |
| Dec 2025 | 0 | — | -83,168,000 | -79,655,000 | 594,734,000 | 104,901,000 | 1,473,768,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-256,018,000
Investing CF
$-88,401,000
Financing CF
$350,633,000
CapEx
$-3,180,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.32
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,091,876,000
Inventory
—
Receivables
—
ST Investments
$388,565,000
EBIT TTM
$-323,116,000
Pretax Income TTM
$-322,161,000
Interest Exp TTM
$-48,000
Analysts
6
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -338,945,000 | -324,248,000 | 594,734,000 | 1,473,768,000 | -879,034,000 | -188,516,000 |
| Dec 2024 | 0 | -260,343,000 | -243,814,000 | 491,240,000 | 1,063,170,000 | -571,930,000 | -134,799,000 |
| Dec 2023 | 0 | -265,737,000 | -241,997,000 | 525,705,000 | 867,078,000 | -341,373,000 | -190,848,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$779,570,000
Forward EPS
$-6.44
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AGEN | AGENUS INC | $280.98M | $6.21 | — |
| EDIT | Editas Medicine, Inc. | $281.67M | $1.83 | — |
| TRXB | TRex Bio, Inc. | $274.46M | $10.00 | — |
| AUTL | Autolus Therapeutics plc | $290.12M | $1.09 | — |
| AGMB | AgomAb Therapeutics NV | $291.55M | $5.92 | — |
News headlines (Yahoo Finance, 1h cache)
Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer
2026-11-17 11:00 · Yahoo
Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
2026-11-12 11:30 · Yahoo
Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029
2026-11-07 00:14 · Yahoo
Eikon Therapeutics to Participate in Multiple Investor Conferences in November
2026-11-02 14:15 · Yahoo
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
2026-10-26 10:00 · Yahoo
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
2026-10-23 13:15 · Yahoo
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
2026-10-18 22:05 · Yahoo
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
2026-10-15 12:00 · Yahoo
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
2026-09-03 11:30 · Yahoo
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
2026-08-22 11:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.